Association of renin-angiotensin system inhibitors with severity and outcomes of COVID-19 infection in hospitalized patients with hypertension

byLucrecia M. Burgos Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are not associated with severity and outcomes of coronavirus disease 2019 (COVID-19) infection in hospitalized patients with hypertension  in Wuhan, China according to a recent study in JAMA Cardiology1. In this retrospective single-centre analysis, the authors analysed hospitalized patients with COVID-19 at the Central HospitalContinue reading “Association of renin-angiotensin system inhibitors with severity and outcomes of COVID-19 infection in hospitalized patients with hypertension”

Impact of the COVID-19 pandemic on interventional cardiology activity

by:Lucrecia Maria Burgos An important reduction in the activity in interventional cardiology has been observed during the COVID-19 epidemic according to a recent study in REC Interventional Cardiology1. The authors carried out a survey in 81 centres involved in ST-elevation myocardial infarction (STEMI) networks in the 17 autonomous communities of Spain. Information was collected on diagnosticContinue reading “Impact of the COVID-19 pandemic on interventional cardiology activity”

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

by:Lucrecia M. Burgos Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the 2019 novel corona virus (2019-nCoV) disease (COVID-19). On the other hand, COVID-19 can, in turn, aggravate the damage to the heart, according to aContinue reading “Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China”

Should cardiovascular disease comorbidity scare you during the COVID-19 season?

by: Dr. Jeemon Panniyammakal, PhD, MPH, FESC The SARS-CoV-2 infection (corona virus infection) spread has reached pandemic proportions. Globally, as on 31 March, 2020 nearly 0.8 million corona virus disease (COVID-19) cases and 38,000 related deaths are reported. Countries around the world are particularly “shielding” or “protecting” individuals with cardiovascular disease (CVD) from external exposureContinue reading “Should cardiovascular disease comorbidity scare you during the COVID-19 season?”

Can the fear of COVID-19 lead to harmful delays in seeking care for cardiovascular emergencies?

by: Darryl Leong The impact of COVID-19 on the delivery of care for emergency cardiovascular illness is unknown. In this report, Tam, et al. describe the timeliness of primary percutaneous coronary intervention for ST elevation myocardial infarction (STEMI) in 7 consecutive patients presenting to a single centre in Hong Kong, China, between January 25, andContinue reading “Can the fear of COVID-19 lead to harmful delays in seeking care for cardiovascular emergencies?”